Raleigh pharma firm to launch migraine drug in early 2022
BioDelivery Sciences International plans to launch in the first quarter of 2022 in the U.S. and Canada an FDA-approved migraine treatment from Dr. Reddy’s Laboratories.
Read More
migraine
